In This Section

Home / News & Media / Oncology Newsfeed

Oncology Newsfeed

FDA Approves Neoadjuvant/Adjuvant Durvalumab for Resectable Non-Small Cell Lung Cancer

On August 15, the US Food and Drug Administration (FDA) approved durvalumab with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery for adults with resectable non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.
For more information read the FDA announcement and the AstraZeneca announcement.
Posted on 8/21/2024

FDA Approves Axatilimab-csfr for Chronic Graft-Versus-Host Disease

On August 14, the US Food and Drug Administration (FDA) approved axatilimab-csfr, a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
For more information read the FDA announcement and the Incyte Corporation announcement.
Posted on 8/19/2024

FDA Approves Daratumumab and Hyaluronidase-fihj for Select Patients with Multiple Myeloma

On July 30, the US Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.
For more information read the FDA announcement and the Johnson & Johnson announcement.
Posted 7/31/2024

Updated NCCN Guidelines Recommend Imetelstat for Symptomatic Anemia in Select Patients

On July 26, Geron Corporation announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of to recommend RYTELO™ (imetelstat) as a Category 1 and 2A treatment of symptomatic anemia in patients with lower-risk Myelodysplastic Syndromes. Treatments are classified as Category 1 and 2A when there is uniform NCCN consensus ≥85% that the intervention is appropriate.
For more information read the Geron announcement.
Posted 7/26/2024

FDA Approves Repotrectinib for Patients with NTRK Gene Fusion-Positive Solid Tumors

On June 13, the US Food and Drug Administration (FDA) granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.
For more information read the FDA announcement and the Bristol Meyers Squibb announcement.
Posted 7/2/2024

FDA Grants Approves Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma

On June 26, the US Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp, a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.
For more information read the FDA announcement and the Genmab Inc. announcement.
Posted 6/27/2024

FDA Approves Adagrasib + Cetuximab for KRAS G12C-Mutated Colorectal Cancer

On June 21, the US Food and Drug Administration (FDA) granted accelerated approval to adagrasib in combination with cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy.
For more information read the FDA announcement and the Bristol Myers Squibb announcement.
Posted 6/24/2024

FDA Approves Selpercatinib for RET Fusion-Positive Thyroid Cancer

On June 12, the US Food and Drug Administration (FDA) approved selpercatinib for adult and pediatric patients 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).
For more information read the FDA announcement.
Posted 6/13/2024